Shots:

• Coloplast has acquired implantable tibial nerve stimulation (ITNS) treatment developer Nine Continents Medical for $145M upfront and an additional contingent milestone. ITNS is developed for overactive bladder (OAB)
• Coloplast expected to initiate clinical studies of ITNS in 2021 with the goal to obtain pre-market approval for a Class III device in the US and EU market approvals in the 2024-2025 timeframe
• ITNS is a miniaturized- self-powered unit placed in the lower leg in a short- minimally invasive procedure under local anesthesia. The unit does not require patient activation- recharging- or recurring visits to the doctor and works on the clinically proven MoA of percutaneous tibial nerve stimulation

  Ref: GlobeNewswire | Image: The Job Network